Aclaris Therapeutics, Inc.

What they do

Aclaris discovers and develops product candidates for immuno-inflammatory diseases using its KINect small molecule kinase discovery platform and an integrated large molecule antibody approach. Its pipeline includes bosakitug (ATI-045), an anti-TSLP monoclonal antibody partnered in from Biosion on an exclusive global license excluding Greater China; ATI-052, an anti-TSLP/anti-IL-4R bispecific antibody; and oral ITK inhibitors including modzatinib (ATI-2138) and ATI-9494. The company also provides contract research services to third parties enabled by its early-stage research capabilities. It is seeking transactions with third-party partners to further develop, obtain marketing approval for and/or commercialize its candidates.

Revenue drivers

• Contract research services — The company states it provides contract research services to third parties enabled by its early-stage research and development expertise; this is the only disclosed revenue-generating activity.
• Company-reported revenue — Total revenue was $7.8M in 2025 and $1.6M in the quarter ended 2026-06-30; the filings provided do not break revenue down by source beyond the contract research services description.
• No product revenue — Aclaris is clinical-stage and describes itself as seeking partners to develop, obtain marketing approval for and/or commercialize its product candidates, indicating no approved-product revenue today.

Recent performance

Annual revenue declined from $31.2M in 2023 to $18.7M in 2024 and $7.8M in 2025, while quarterly revenue was $3.3M, $1.3M, $2.0M and $1.6M across the four most recent quarters. Net losses were $132.1M in 2024 and $64.9M in 2025, with operating cash use of $20.1M in 2024 and $47.1M in 2025. As of 2026-06-30 the company reported total assets of $179.7M, total liabilities of $55.1M and shareholder equity of $124.6M. The August 6, 2026 earnings release stated cash, cash equivalents and marketable securities of $170.6M as of June 30, 2026, compared with $151.4M previously.

Strategy

Management is prioritizing clinical execution across its antibody and ITK inhibitor pipeline while seeking third-party partners for development, approval and commercialization. It initiated a Phase 2 trial of bosakitug in 109 moderate-to-severe atopic dermatitis patients in June 2025, with top-line data expected in the fourth quarter of 2026. ATI-052 Phase 1b proof-of-concept trials in atopic dermatitis and asthma are ongoing, with a Phase 2b program expected to start with an asthma trial in the fourth quarter of 2026. A multi-part Phase 2b trial of modzatinib in lichen planus is planned for the fourth quarter of 2026, and an IND for ATI-9494 is expected in the fourth quarter of 2026.

Risks

• No approved products or profitability — The company has incurred significant losses since inception, expects losses over the next several years and may never achieve or maintain profitability.
• Additional funding needs — Aclaris states it will need substantial additional funding and, if unable to raise capital when needed, could be forced to curtail planned operations.
• Dependence on partners and third parties — Its business depends on identifying and consummating transactions with third-party partners, and it relies heavily on third parties for clinical trials, manufacturing and development support.
• Clinical and competitive uncertainty — If it cannot successfully develop its candidates or experiences significant delays, its business will be harmed, and it faces substantial competition that may bring drugs to market first or more successfully.

Outlook

Management reaffirmed expected top-line results from two Phase 1b ATI-052 proof-of-concept trials and the Phase 2 bosakitug atopic dermatitis trial in the second half of 2026. It intends to initiate a Phase 2b ATI-052 program in asthma in the fourth quarter of 2026, begin startup activities for an ATI-052 atopic dermatitis Phase 2b trial and an eosinophilic esophagitis POC trial, and start a Phase 2b modzatinib trial in lichen planus. The company also expects to file an IND for ATI-9494 in the fourth quarter of 2026. The August 2026 release stated a strong cash runway expected to enable development of the pipeline through the end of 2028.